Hanspeter Gerber
Chief Scientific Officer Sutro Biopharma
Dr. Hans-Peter Gerber is Chief Scientific Officer at Sutro Biopharma, leading the research organization. With 30 years of R&D experience in oncology drug development, he has contributed to the development of 6 of the 15 approved ADCs.
Previously, Hans-Peter co-founded Codeable Therapeutics, served as CSO and SVP at 3T Biosciences, and built the R&D organization at Maverick Therapeutics. Between 1995 and 2017, Hans-Peter held increasing responsibilities at Genentech, Seattle Genetics, and Pfizer. As an internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed papers and holds over 100 patents.
Seminars
- Exploring rationale for dual payload ADCs, combining synergetic efficacy of Topo1 payloads combined with diverse, alternative mechanisms to overcome patient resistance
- Spotlighting comprehensive preclinical efficacy of dual payload ADCs across in vitro and in vivo models
- Supporting promising efficacy results with preclinical pharmacology, PK/PD and safety profiles of dual cytotoxic conjugate
- Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
- Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
- Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
- Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design
As the ADC field matures beyond the large-scale pharma M&A deal-making from 2024, there continues to be a stream of licensing and partnerships activity as the community looks to leverage novel science and technologies to develop the next generation of targeted oncology therapies. Further driven by an increasingly crowded landscape and heightened need to develop differentiated ADCs, the bar has been raised to develop novel ADCs that will be backed by life science investors and attract the attention of pharma and biotech collaborators.
Exclusively designed for search and evaluation, external evaluation, and business development leads, C level biotech leaders, and VC biopharma investors, the ADC Licensing, Partnering & Investment Panel is the place to be to understand diverse perspectives on what ADC innovation is showing most promise, how best to balance novelty versus risk to investors, and biopharma decision-maker attitudes when evaluating ADC deal-making opportunities in 2026.
Open to all registered attendees, join to be part of an insightful panel session followed by an informal networking opportunity to foster new relationships for ADC collaboration, partnerships and investment.
Panel Discussion Highlights:
- Contextualising the current state of investment and deal-making in the ADC field: What direction if the field headed as it crests the Topo1 wave?
- Breaking down different avenues for ADC differentiation to understand what is showing promise and predict where the ADC field will be in 3-5 years
- Delving into investor perspectives to help set up ADC companies in Series A funding for success
- Understanding pharma and biotech attitudes towards required data, level of risk, and differentiating factor when deciding which ADC programmes to explore licensing and partnering
- Debating the factors contributing towards the go/no-go decision in the clinic to move towards licensing and partnership conversations
